130 related articles for article (PubMed ID: 36192013)
1. Long-term Outcomes and Prognostic Factors of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma.
Nagata K; Sasaki R; Iwatsu S; Fukushima M; Haraguchi M; Yamamichi S; Miuma S; Miyaaki H; Taura N; Yamazaki T; Nakao K
Anticancer Res; 2022 Oct; 42(10):5001-5007. PubMed ID: 36192013
[TBL] [Abstract][Full Text] [Related]
2. The Role of the Albumin-Bilirubin Score for Predicting the Outcomes in Japanese Patients with Advanced Hepatocellular Carcinoma Treated with Ramucirumab: A Real-World Study.
Hatanaka T; Naganuma A; Shibasaki M; Kohga T; Arai Y; Nagashima T; Ueno T; Namikawa M; Saito S; Hoshino T; Takizawa D; Arai H; Makita F; Kakizaki S; Harimoto N; Shirabe K; Uraoka T
Oncology; 2021; 99(4):203-214. PubMed ID: 33279908
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic body radiotherapy in hepatocellular carcinoma: patient selection and predictors of outcome and toxicity.
Loi M; Comito T; Franzese C; Dominici L; Lo Faro L; Clerici E; Franceschini D; Mancosu P; Reggiori G; Gallo P; Badalamenti M; Scorsetti M
J Cancer Res Clin Oncol; 2021 Mar; 147(3):927-936. PubMed ID: 32945972
[TBL] [Abstract][Full Text] [Related]
4. Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma.
Hiraoka A; Kumada T; Tada T; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Toyoda H; Ohama H; Tsutsui A; Itokawa N; Hayama K; Arai T; Imai M; Nakamura S; Michitaka K; Hiasa Y; Kudo M;
Oncology; 2020; 98(5):295-302. PubMed ID: 32097925
[TBL] [Abstract][Full Text] [Related]
5. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.
Ananchuensook P; Sriphoosanaphan S; Suksawatamnauy S; Siripon N; Pinjaroen N; Geratikornsupuk N; Kerr SJ; Thanapirom K; Komolmit P
BMC Gastroenterol; 2022 Jun; 22(1):295. PubMed ID: 35701739
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis.
Hiraoka A; Kumada T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Imai M; Joko K; Koizumi Y; Hiasa Y; Michitaka K; Kudo M;
Cancer Med; 2019 Jul; 8(8):3719-3728. PubMed ID: 31127698
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Toxicity of Stereotactic Body Radiotherapy for Early to Advanced Stage Hepatocellular Carcinoma - Initial Experience From an Australian Liver Cancer Service.
Liu HY; Lee Y; McLean K; Leggett D; Hodgkinson P; Fawcett J; Mott R; Stuart K; Pryor D
Clin Oncol (R Coll Radiol); 2020 Oct; 32(10):e194-e202. PubMed ID: 32345457
[TBL] [Abstract][Full Text] [Related]
8. The role of albumin-bilirubin grade and inflammation-based index in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy.
Gkika E; Bettinger D; Krafft L; Schultheiss M; Neeff HP; Maruschke L; Schulenburg M; Adebahr S; Kirste S; Nestle U; Thimme R; Grosu AL; Brunner TB
Strahlenther Onkol; 2018 May; 194(5):403-413. PubMed ID: 29322205
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma.
Kim N; Cheng J; Jung I; Liang J; Shih YL; Huang WY; Kimura T; Lee VHF; Zeng ZC; Zhenggan R; Kay CS; Heo SJ; Won JY; Seong J
J Hepatol; 2020 Jul; 73(1):121-129. PubMed ID: 32165253
[TBL] [Abstract][Full Text] [Related]
10. Chronological change in serum albumin as a prognostic factor in patients with hepatocellular carcinoma treated with lenvatinib: proposal of albumin simplified grading based on the modified albumin-bilirubin score (ALBS grade).
Kariyama K; Hiraoka A; Kumada T; Yasuda S; Toyoda H; Tsuji K; Hatanaka T; Kakizaki S; Naganuma A; Tada T; Takaguchi K; Itobayashi E; Ishikawa T; Shimada N; Tsutsui A; Nagano T; Imai M; Nakamura S; Wakuta A; Miyake N; Shiota S; Nouso K
J Gastroenterol; 2022 Aug; 57(8):581-586. PubMed ID: 35763116
[TBL] [Abstract][Full Text] [Related]
11. Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion.
Mathew AS; Atenafu EG; Owen D; Maurino C; Brade A; Brierley J; Dinniwell R; Kim J; Cho C; Ringash J; Wong R; Cuneo K; Feng M; Lawrence TS; Dawson LA
Eur J Cancer; 2020 Jul; 134():41-51. PubMed ID: 32460180
[TBL] [Abstract][Full Text] [Related]
12. Baseline Albumin-Bilirubin (ALBI) Score in Western Patients With Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy (SBRT).
Murray LJ; Sykes J; Brierley J; Kim JJ; Wong RKS; Ringash J; Craig T; Velec M; Lindsay P; Knox JJ; Dawson LA
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):900-909. PubMed ID: 29976502
[TBL] [Abstract][Full Text] [Related]
13. Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.
Hiraoka A; Kumada T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Imai M; Joko K; Tanaka H; Tamai T; Koizumi Y; Hiasa Y; Michitaka K; Kudo M; ;
Oncology; 2019; 97(5):277-285. PubMed ID: 31307035
[TBL] [Abstract][Full Text] [Related]
14. Application of the albumin-bilirubin grade for predicting prognosis after curative resection of patients with early-stage hepatocellular carcinoma.
Ma XL; Zhou JY; Gao XH; Tian L; Wu J; Zhang CY; Zhou Y; Dai Q; Wang BL; Pan BS; Yang XR; Guo W
Clin Chim Acta; 2016 Nov; 462():15-22. PubMed ID: 27520748
[TBL] [Abstract][Full Text] [Related]
15. Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve.
Tomonari T; Tani J; Sato Y; Tanaka H; Tanaka T; Taniguchi T; Asahiro M; Okamoto K; Sogabe M; Miyamoto H; Muguruma N; Masaki T; Takayama T
Cancer Med; 2023 Feb; 12(3):2646-2657. PubMed ID: 35964253
[TBL] [Abstract][Full Text] [Related]
16. Dual hepatitis B and C-associated hepatocellular carcinoma: clinical characteristics, outcome, and prognostic role of albumin-bilirubin grade.
Ko CC; Ho SY; Liu PH; Hsu CY; Hsia CY; Huang YH; Su CW; Lei HJ; Lee RC; Hou MC; Huo TI
Int J Clin Oncol; 2022 Apr; 27(4):739-748. PubMed ID: 35119581
[TBL] [Abstract][Full Text] [Related]
17. Modified albumin-bilirubin predicted survival of unresectable hepatocellular carcinoma patients treated with immunotherapy.
Navadurong H; Prasoppokakorn T; Siriwong N; Phathong C; Teeyapun N; Tanasanvimon S; Thanapirom K; Komolmit P; Tangkijvanich P; Treeprasertsuk S; Chaiteerakij R
World J Gastrointest Oncol; 2023 Oct; 15(10):1771-1783. PubMed ID: 37969413
[TBL] [Abstract][Full Text] [Related]
18. Impact of modified albumin-bilirubin grade on survival in patients with HCC who received lenvatinib.
Tada T; Kumada T; Hiraoka A; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Tani J; Nakamura S; Nouso K; Tsutsui A; Nagano T; Takaaki T; Itokawa N; Okubo T; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y;
Sci Rep; 2021 Jul; 11(1):14474. PubMed ID: 34262065
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic outcome and related predictors of stereotactic body radiotherapy for small liver-confined HCC: a systematic review and meta-analysis of observational studies.
Long Y; Liang Y; Li S; Guo J; Wang Y; Luo Y; Wu Y
Radiat Oncol; 2021 Apr; 16(1):68. PubMed ID: 33832536
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Meta-Analysis and International Stereotactic Radiosurgery Society Practice Guidelines.
Bae SH; Chun SJ; Chung JH; Kim E; Kang JK; Jang WI; Moon JE; Roquette I; Mirabel X; Kimura T; Ueno M; Su TS; Tree AC; Guckenberger M; Lo SS; Scorsetti M; Slotman BJ; Kotecha R; Sahgal A; Louie AV; Kim MS
Int J Radiat Oncol Biol Phys; 2024 Feb; 118(2):337-351. PubMed ID: 37597757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]